News

Assessing Greenbrier's Q1 Earnings Forecast and Analyst Ratings

Assessing Greenbrier's Q1 Earnings Forecast and Analyst Ratings

Greenbrier Companies Prepare for Upcoming Q1 Earnings Report

The Greenbrier Companies, Inc. (NYSE: GBX) is set to announce its financial results for the first quarter soon. Many investors are closely monitoring this announcement, as analysts project significant improvements compared to the previous year.

Annual Growth Expectations

Analysts are forecasting that Greenbrier will report earnings of $1.15 per share for this quarter. This is a notable increase from last year’s earnings of 96 cents per share. Alongside this improvement, the forecasted revenue is projected to reach approximately $849.51 million, compared to $808.8 million from a year earlier. This upward trend reflects the company's resilience and growth in a competitive market.

Recent Performance Insights

In an interesting development, Greenbrier reported better-than-expected results for its fourth quarter on October 23. This positive trajectory has caught the attention of investors and stock analysts alike, leading to diverse forecast updates.

Stock Price Movement

However, despite the optimistic forecasts, shares of Greenbrier experienced a slight decline of 1.2%, closing at $61.29 on the previous Monday. This fluctuation may have raised questions among investors about the stability and future direction of the company’s stock.

Analyst Rating Updates

With Greenbrier gearing up for its Q1 earnings, let's delve into how notable analysts are currently rating the company:

B of A Securities

Ken Hoexter maintained an Underperform rating, adjusting the price target from $42 to $50 on October 24. Hoexter has shown an accuracy rate of 66%, indicating his analysis carries substantial weight in the financial community.

Susquehanna

Analyst Bascome Majors upheld a Positive rating, increasing the price target from $63 to $65 on October 21. His accuracy rate of 60% suggests a level of confidence in his projections, reflecting a more upbeat forecast.

Stephens & Co.

Justin Long kept an Overweight rating and raised his price target from $62 to $65 on April 8. Long’s accuracy rate of 71% implies strong performance expectations for Greenbrier over the coming quarters.

Investment Considerations for GBX

For those considering investing in GBX stock, these varied analyst ratings and updated price targets could provide crucial insights. Looking at how these assessments align with current market trends will be vital for making informed decisions.

Frequently Asked Questions

What is The Greenbrier Companies, Inc. known for?

The Greenbrier Companies, Inc. specializes in manufacturing and servicing railcars, making it a key player in the transportation sector.

What are the expected earnings per share for Greenbrier this quarter?

Analysts expect Greenbrier to report earnings of $1.15 per share for the upcoming quarter.

How did Greenbrier perform in the previous quarter?

Greenbrier posted better-than-expected results for its fourth quarter according to their report on October 23.

What was the closing price of Greenbrier shares recently?

Greenbrier shares closed at $61.29 recently, reflecting a slight decline of 1.2%.

What do analysts think about Greenbrier's future performance?

Analysts have provided varied ratings and targets, indicating both confidence and caution regarding Greenbrier’s future market performance.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Testing Grounds: Navigating PRN Test Insights

Updated Category News Views 1

Deciphering the PRN Tester Repetition Today we're staring at what feels like déjà vu—a simple PR test peppered with the classic sentence about a fox and a dog. It's like someone left the 'repeat' function stuck on during a slow day at the office. But hey, let’s dig in. Is there something more behind this repetitive text, or are we grumbling at a wall? Unpacking the...

Continue Reading
TECNO's Modular Phone and Mini-PC Win Big at IFA 2026

Updated Category News Views 1

The Tale of Two Game-Changers TECNO has just scooped up two big-time awards, and I'm here to break it down like no glossy magazine ever could. Picture this: a brand that knows how to keep its foot on the innovation pedal and doesn't shy away from shaking up the tech world. TECNO's got the goods, claiming two prestigious IFA Global Product Technology Innovation Awards this...

Continue Reading
HKC and KOORUI Shine Bright at 2026 Berlin Awards

Updated Category News Views 3

Display Titans Take Center Stage in Berlin Look, in this game of display tech, you either adapt or get left in the dust. At the 2026 Global Product Technology Innovation Awards in Berlin, we saw two names rise to the top—HKC and its acclaimed brand KOORUI. They didn't just show up; they grabbed the spotlight with two major honors. Award Spotlights: A Breakdown HKC took...

Continue Reading
Signant and Lothar Forge Future in Clinical Trials

Updated Category News Views 2

Breathing New Life into Clinical Trials Alright, folks, listen up. We've got a fresh collaboration cooking that could shake things up in the clinical trial sector. Signant Health, a heavyweight in clinical trial solutions, has teamed up with Lothar Medical, and they’ve hitched their wagons to launch something rather intriguing: the ALDS PRO pulmonary function tech. Let...

Continue Reading
LiberNovo Spotlights Ergonomic Seating at Berlin's IFA 2026

Updated Category News Views 1

LiberNovo Sets the Stage at IFA 2026 If you're poking around Berlin this September, the Messe Berlin is the place to be, especially for those keeping tabs on the consumer tech world. LiberNovo, the ergonomic seating company you might not have had on your radar, is out here making noise. They're throwing down the gauntlet with the Maxis Series, promising a better deal for...

Continue Reading
Affleck Joins Aflac in Unlikely Yet Fitting Alliance

Updated Category News Views 2

A Partnership Born from a Punning Connection Look, in this world of insurance and Hollywood glitz, it's not every day you see Ben Affleck sharing the screen with a talking duck. But here we are. Aflac—the giant in supplemental health insurance—and Ben Affleck have cozied up for a series of ads under Affleck’s direction, breathing life into what started as nothing...

Continue Reading
Hims & Hers Faces Legal Storm Over Alleged Privacy Breaches

Updated Category News Views 4

Legal Storms Brew Over Alleged Privacy Breaches Well, here we go again, folks. Just when you think the waters are calming, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself in the thick of a nasty securities fraud class action lawsuit. Allegedly they've been less than honest with their customers' health info—something about sneaking around with people's sensitive data...

Continue Reading
Evolve & ELITEWHEELS: Shifting Gears in European Cycling

Updated Category News Views 3

Revving Up for the European Cycling Scene There's something about the open road and the whirr of wheels that gets blood pumping—maybe it's the competition, maybe it's the gear. Either way, this year's Italian Bike Festival is turning the Misano World Circuit into a battleground for cycling's elite, with evolve and ELITEWHEELS charging at the forefront. They're not just...

Continue Reading
Virterion Surges Ahead in VPS Racing With Reliable Hosting

Updated Category News Views 3

Why Virterion Stands Out in 2026 VPS Landscape For anyone knee-deep in the hosting game, you know the market's got more players than a late-night poker round. Virterion, though—that's a name carving out a noticeable niche, and for solid reasons. In 2026, the backdrop's not just speed, it’s about matching technology and support with what ambitious developers need. VPS...

Continue Reading
Roborock Fuels Market Surge with 27.6% Revenue Boost

Updated Category News Views 1

Roborock's Rocket-Like Ascent in Global Markets Call me impressed, but Roborock is really hitting its stride. The company's been on a tear, pulling in RMB 10.084 billion during the first half of 2026—a remarkable 27.6% bump from last year. Not just content with the revenue surge, they also saw net profits jump 45.6%, making it pretty clear that they're not just playing...

Continue Reading

Top 5 Most Recently Viewed Articles

Talisker Resources Successfully Closes Gold-Linked Note Deal

Updated Category News Views 49

Talisker Resources Announces Successful Financing Initiative Talisker Resources Ltd. (TSK) has made headlines with the completion of its latest financing venture involving $1.33 million through the issuance of gold-linked notes. This strategic move is set to propel the progress of Talisker's flagship project, the Bralorne Gold Project, which is currently undergoing...

Continue Reading
FDA Approves Novartis' Kisqali, Expanding Breast Cancer Treatment

Updated Category News Views 133

FDA Approves Novartis' Kisqali: A Major Step Forward in Breast Cancer Care Novartis (NYSE: NVS) has reached a crucial milestone with the FDA's approval of Kisqali (ribociclib), now available for a broader group of patients facing early-stage breast cancer. This approval represents a significant leap in treating hormone receptor-positive/human epidermal growth factor...

Continue Reading
Mounting Challenges for Mobileye N.V: Insights into Stock Outlook

Updated Category News Views 101

Mobileye Faces Downgrade as Transition Year Approaches Recently, UBS has revised its outlook on Mobileye N.V (NASDAQ:MBLY), a leader in autonomous driving technologies. The firm has downgraded the stock from Buy to Neutral, with a lowered price target of $14.00, decreasing from an earlier target of $20.00. This decision is primarily due to the company's current struggles,...

Continue Reading
Plans for Spending Cuts and Subsidy Eliminations Revealed

Updated Category News Views 118

Plans for Federal Spending Cuts and Subsidy Eliminations John Paulson, a billionaire investor known for his connections with former President Donald Trump, has outlined his strategy for significant federal spending reductions if he were to be appointed as Treasury Secretary. Collaborating with Elon Musk, Paulson seeks to minimize government expenditures, particularly by...

Continue Reading
Brazil’s Finance Minister Prepares for Key Fiscal Announcements

Updated Category News Views 35

Brazil's Finance Minister Prepares for Key Fiscal Announcements Brazil's Finance Minister Fernando Haddad has recently indicated that significant fiscal measures aimed at supporting the country’s financial framework might be unveiled shortly. This announcement comes as the government approaches the final stages of preparation for what could be a pivotal moment in...

Continue Reading